FDA Home Page | Search
FDA Site | FDA A-Z Index | Contact
FDA | FDA Centennial
Action packages for 77 products were studied (14 BLAs and 63 NDAs). Thirty-six (36) action packages, or 47%, were for products approved on the first cycle of review (7 BLAs and 29 NDAs).
Question: What best practices led to first cycle approvals?
Forty-one (41) action packages, or 53%, were for products having multi-cycle reviews.
Of those products having multi-cycle reviews, 18 (5 BLAs and 13 NDAs) or 23%, were approved after additional reviews when the study was started.
Question: Could anything have been done to avoid multi-cycle review?
Twenty (20) products (2 BLAs and 18 NDAs) or 25%,were deemed approvable after additional reviews at the time of the study. Three (3) NDAs were deemed NA after additional reviews at the time of the study.
Return to First Cycle Review Performance Report
Stage 1-For the study, the hypothesis and metric generation was done first, followed by review of the action package. From the review the team created a word summary, which was analyzed qualitatively, and also completed a data collection instrument, which was analyzed quantitatively. From these two sources came the emerging themes and recommendations.
Stage 2-After the development of the emerging themes and recommendations came the validation of the themes and recommendations, and the division-level interviews on philosophies and best practices. The themes and recommendations, and the results of the interviews, were combined to generate the improvement opportunities.
Return to First Cycle Review Performance Report
RPM (Regulatory Project Manager) Product Summary Comments (Review of product summaries of 23 action packages, which was approximately one-third of the cohort, were reviewed with regulatory project managers for accuracy)
Of the comments by RPMs, 46% were editorial in nature, 29% elaborated on the nature of a critical issue, 13% suggested an alternative critical issue, 8% made changes to the narrative timeline, and 4% had additional meeting minutes to contribute.
Return to First Cycle Review Performance Report
For self-originated drugs (those originated in-house) 42% were approved in a single cycle and 58% in multi-cycles. For in-licensed drugs (those originated externally) 65% were approved in a single cycle and 35% in multiple cycles.
Return to First Cycle Review Performance Report
For reviews having Advisory Committee meetings, 31% (n=4) were approved in a single cycle and 69% (n=9) in multiple cycles. For reviews not having Advisory Committee meetings, 46%(n=25) were approved in a single cycle and 54% (n=29) in multiple cycles.
Return to First Cycle Review Performance Report
a. The first cycle approval rate for sponsors that had drugs approved previously by the FDA was 51% of 47 submitted compared to 30% of 20 submitted for sponsors with no prior approved drugs.
b. The first cycle approval rate for sponsors that had drugs approved previously by the FDA was 53% of the 38 products in the same therapeutic area, compared to 44% of the 9 products in same therapeutic area. Note: Not including DESI, 505(b)(2) drugs
Return to First Cycle Review Performance Report
a. EOP2 Meeting--
Of the 46 application reviews that had EOP2 meetings, 52% were reviewed in one cycle and 48% in multiple cycles. Of those that did not have a EOP2 meeting, 29% were reviewed in one cycle and 71% in multiple cycles.
b. Timing of Issue ID for Multi Cycle Products with EOP2 Meeting--
Of the 22 applications that had EOP2 meetings and were reviewed in multiple cycles, 23% had the key issue identified at the EOP2 meeting, 36% at the Pre-NDA meeting and 41% during the review.
Return to First Cycle Review Performance Report
a. Pre-NDA/BLA Meeting --Of the 58 application reviews that had Pre-NDA/BLA meetings, 47% were reviewed in one cycle and 53% in multiple cycles. Of those that did not have a Pre-NDA/BLA meeting, 33% were reviewed in one cycle and 67% in multiple cycles.
b. Timing of Pre-NDA/BLA Meeting--Of the applications that had Pre-NDA/BLA meetings, 24 had the Pre-NDA/BLA meeting less than 6 months before application submission. Of those, 46% were reviewed in one cycle and 54% in multiple cycles. Of the 34 that had a Pre-NDA/BLA meeting more than 6 months before submission, 58% were reviewed in one cycle and 41% in multiple cycles.
For those applications that had Pre-NDA/BLA meetings, the findings were the same relative to review in one cycle or multiple cycles for applications with or without an EOP2 meeting.
Return to First Cycle Review Performance Report
a. Percent of Applications with Significant Pre-Submission Issues Resolved by First Action
Of those applications with significant Pre-submission issues 29% (7) were resolved by first action, and 71% (17) were not resolved.
b. Percent of Applications with Significant Issues Identified Pre-Submission and Resolved by First Action
Of those 7 applications with significant pre-submission issues resolved by first action, only about 20% involved safety or efficacy issues, while three quarters involved trial execution or trial design.
Pre-submission meetings identified major issues in 24 products—in some cases, more than one major issue was identified; 17 drugs required more than 1 review cycle.
Return to First Cycle Review Performance Report
Three timelines show the disposition of Products G, A, and H.
Review of Product G:,
Review of Product A:
Review of Product H:
Return to First Cycle Review Performance Report
Failure of Early ID
Root Cause:
Leads to:
Unclear Problem Resolution Plan
Root Cause:
Leads to:
Lack of Priority
Root Cause:
Leads to:
Variability in Standards
Root Cause:
quot;Check and Follow Upquot; Communication
Step 0—Development plan quot;Checklistquot;
Step 1--Sponsor-FDA discussion
Step 2—Meeting minutes: sign-off on action items
Step 3—Follow-up; issue clarification and alignment
Step 4—Sponsor's plan of action
Step 5—Evaluation of plan by FDA
Step 6—back to Step 1 if necessary
Return to First Cycle Review Performance Report
a. Total Number of Communications
Single-cycle applications:
Average number of communications between FDA and sponsor was 25.
Application designation— first, second, third |
Number of Communications Between FDA and Sponsor | NDA/ BLA |
---|---|---|
1 | 1 | NDA |
2 | 4 | NDA |
3 | 5 | NDA |
4 | 6 | NDA |
5 | 7 | NDA |
6 | 7 | NDA |
7 | 7 | NDA |
8 | 8 | NDA |
9 | 12 | NDA |
10 | 13 | BLA |
11 | 15 | NDA |
12 | 15 | NDA |
13 | 16 | NDA |
14 | 18 | NDA |
15 | 18 | NDA |
16 | 19 | NDA |
17 | 24 | NDA |
18 | 26 | NDA |
19 | 28 | NDA |
20 | 30 | BLA |
21 | 33 | BLA |
22 | 35 | NDA |
23 | 38 | NDA |
24 | 38 | BLA |
25 | 41 | BLA |
26 | 41 | NDA |
27 | 45 | NDA |
28 | 52 | BLA |
29 | 62 | NDA |
30 | 92 | BLA |
Multi-cycle applications:
Average number of communications between FDA and sponsor was 21.
Application designation— first, second, third |
Number of Communications Between FDA and Sponsor | NDA/ BLA |
---|---|---|
1 | 1 | BLA |
2 | 4 | NDA |
3 | 6 | NDA |
4 | 7 | NDA |
5 | 7 | BLA |
6 | 8 | NDA |
7 | 8 | NDA |
8 | 8 | BLA |
9 | 10 | NDA |
10 | 10 | BLA |
11 | 12 | NDA |
12 | 12 | NDA |
13 | 13 | NDA |
14 | 13 | NDA |
15 | 14 | NDA |
16 | 14 | NDA |
17 | 15 | NDA |
18 | 15 | NDA |
19 | 16 | NDA |
20 | 17 | NDA |
21 | 18 | NDA |
22 | 18 | NDA |
23 | 20 | BLA |
24 | 21 | NDA |
25 | 22 | BLA |
26 | 23 | NDA |
27 | 25 | NDA |
28 | 27 | NDA |
29 | 30 | NDA |
30 | 30 | NDA |
31 | 31 | NDA |
32 | 38 | NDA |
33 | 40 | NDA |
34 | 42 | NDA |
35 | 43 | NDA |
36 | 56 | NDA |
37 | 81 | NDA |
Excluding DESI, 505(b)(2) drugs
Packages with no communications omitted from graphs and average calculations.
Source: BAH analysis
b. Distribution Throughout Review Cycle (per application)
Elapsed Time in Review Cycle (Shown as fraction of total review time) | Communications per Application— Single-cycle applications |
Communications per Application— Multiple-cycle applications |
---|---|---|
0 | ||
0.2 | 1.3 | 1.4 |
0.4 | 2.9 | 3 |
0.6 | 3.2 | 4.3 |
0.8 | 4.5 | 5 |
1 | 11.2 | 6.6 |
Increase for single-cycle applications in the final 20 percent of the review cycle likely due to finalizing open issues (e.g., labeling)
Note: Similar findings observed for analysis by issues sub-type (e.g., CMC)
Return to First Cycle Review Performance Report
For Product B: Manufacturing facility issues were the key ones cited in the first action letter, which was issued 302 days after submission. These issues were initially communicated to the sponsor 30 days before the action date. The sponsor resubmitted the application and resolved the issues 40 days after the first action date. The product was approved on Day 380, representing a delay of approximately 3 months.
For Product Q: FDA communicated to the Sponsor cGMP issues approximately 150 days before the date of the first action letter, which issued on Day 300. The sponsor corrected deficiencies and resubmitted the application approximately 20 days after the first action letter. The product was approved on Day 503, representing a delay of about 7 months.
Return to First Cycle Review Performance Report
For Product R: Initial communication concerning deficiencies and additional clinical endpoint study needed occurred about 80 days after submission. These issues were resolved approximately 80 days later and the product was approved on Day 183.
For Product S: Initial communication concerning cGMP and Phase 4 immunogenicity issues occurred about 170 days after submission. These issues were resolved approximately 100 days later and the product was approved on Day 277.
For Product T: Initial communication concerning facility deficiencies and carcinogenicity issues occurred shortly after submission. These issues were resolved approximately 280 days before the product's first action date and the product was approved on Day 302.
Return to First Cycle Review Performance Report
After Submission, the internal planning meeting occurs. The objectives of this meeting are to:
Between Submission and Filing, is the Sponsor presentation (which is most beneficial when conducted before the Filing meeting). The objectives of this meeting are:
Between Filing and First Action, is the mid-Cycle Meeting. The objectives of this meeting are:
From Submission to Filing to First Action there is ongoing FDA-Sponsor Communication
Note: internal planning meetings and sponsor presentations are most beneficial when conducted before the Filing Meeting
Return to First Cycle Review Performance Report
a. Percent of approved drugs with post-marketing commitments by cycle
For drugs approved on the first cycle, 80 percent had post-marketing commitments (n=24) and 20 percent (n=6) did not have them. For drugs approved in multiple cycles, 88 percent had post-marketing commitments (n=15) and 12 percent (n=2) did not have them.
(Note: Did not include DESI, 505(b)(2) drugs)
b. Approvals with post-marketing commitments by number of commitments
For drugs approved on the first cycle, 20% had no post-marketing commitments (n=6), 27% had 1 to 4 commitments (n=8), 33% had 5 to 8 commitments (n=10), and 20% had 9 or more commitments (n=6). For drugs approved in multiple cycles, 12% had no post-marketing commitments (n=2), 47% had 1 to 4 commitments (n=8), 35% had 5 to 8 commitments (n=6), and 16% had 9 or more (n=1). Average number of commitments per approval was 5.4 for first cycle approvals and 4.4 for multi-cycle approvals.
Return to First Cycle Review Performance Report
a. Commitments by Area of Focus
Area of Focus (Studies to demonstrate safety and efficacy are counted as two areas of focus) |
First Cycle Approvals: 30 products, 167 PMCs * |
Multi-Cycle Approvals: 17 products, 68 PMCs * |
---|---|---|
Safety | 45, 26% | 17, 25% |
CMC | 20, 12% | 14, 21% |
Pharm-Tox (non-clin.) | 8,5% | 12, 18% |
Drug-Drug Interaction | 10, 6% | 1, 1% |
Efficacy | 41, 25% | 5, 7% |
Patient sub-pop. | 16, 10% | 10, 15% |
ADME (clinical) | 24, 14% | 7, 10% |
Education/Labeling | 3, 2% | 2, 3% |
(1) Includes post-marketing commitments from 39 submissions
(2) Does not Include DESI, 505(b)(2) products
(*): Studies to demonstrate safety and efficacy are counted as two areas of focus
b. Type of Post Marketing Commitment
Type of Post Marketing Commitment | First Cycle Approvals: 30 products, 162 PMCs |
Multi-Cycle Approvals: 17 products, 75 PMCs |
---|---|---|
New Clinical Study | 79, 49% | 38, 50% |
Non-Clinical Study | 19, 12% | 4, 5% |
Continue/Extend Study | 54, 33% | 23, 31% |
Submit Report Data | 10, 6% | 2, 3% |
Unknown | 0 | 8, 11% |
Return to First Cycle Review Performance Report
Disposition of deficiencies | a. CMC | b. Non-CMC |
---|---|---|
Full compliance with FDA requests | 9, 100% | 8, 49% |
New agreement for issue resolution | 4, 25% | |
Became post-marketing commitment upon approval | 2, 13% | |
Unknown | 2, 13% |
Analysis includes 18 multi-cycle approved products, some had >1 major issue.
Source: BAH Analysis
Return to First Cycle Review Performance Report
a. Number of Submissions by Quarter (aggregate 2001-2004*)—1st Quarter,11; 2nd Quarter, 12;
3rd Quarter, 19; 4th Quarter, 35.
Similar findings observed for individual years.
b. Approval Rate by Quarter Submitted—1st Quarter, 0.64; 2nd Quarter, 0.58; 3rd Quarter, 0.68;
4th Quarter, 0.26. Average: 47%
Findings do not change based on application priority status.
Return to First Cycle Review Performance Report
Total Number of Issues per Application:
1st Quarter, 41; 2nd Quarter, 21; 3rd Quarter, 41; 4th Quarter, 36. Average: 36.
Key issues per Application by Type:
Formatting issues--1st Quarter, 5.2, 2nd Quarter, 1.9; 3rd Quarter, 10; 4th Quarter, 5.5. Average: 5.7
Safety issues—1st Quarter, 11; 2nd Quarter, 6; 3rd Quarter, 13; 4th Quarter, 9. Average: 10.0
Efficacy issues—1st Quarter, 8.1, 2nd Quarter, 3.1, 3rd Quarter, 4.7; 4th Quarter, 6. Average: 5.5
Sources: BAH Analysis; Division Interviews
Return to First Cycle Review Performance Report
For applications needing a foreign inspection, 50% of them were first cycle approvals and 50% were multiple cycle approvals (n=56). For applications needing a domestic inspection, 38% of them were single-cycle reviews and 62% were multiple-cycle reviews (n=21).
Return to First Cycle Review Performance Report
CGMP Inspection process is a timeline starting with NDA submission, followed 2-6 weeks later by the Filing meeting, followed 1-2 days later by Determination of Inspection necessity, which requires the notification of the Office of Compliance and the Field office. Field planning takes about 1-3 months (longer for foreign sites (permits)) before the inspection occurs. That takes about 10 days, followed 2-3 weeks later by the documentation of the report on results. Review by the Office of Compliance takes about 4 days followed by their recommendation. The inspection process takes 2-4 months to complete. Improvements in this process can be made by early involvement at the pre-submission or Filing meeting stage, and by streamlined planning and coordination of the inspection.